Inc. Abb Vie's insider trading at Reata Pharmaceuticals
SEC Form 4 filings for AbbVie Inc.,

Insider trading of Inc. Abb Vie, a 10% owner at RETA Reata Pharmaceuticals, Inc.

Most recently Inc. Abb Vie sold 450,000 shares worth $10,125,000.00 on 28 March 2017.

Insider Title
Shares Price per share Total price Shares after Source
2017-03-28 Inc. Abb Vie
10% owner
10% owner Sale 450,000 $22.50 $10,125,000
Reata Pharmaceuticals, Inc. logo

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Its lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreich's ataxia, mitochondrial myopathies, and metastatic melanoma. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.

  • Reata Pharmaceuticals, Inc., 2801 Gateway Drive, Irving 75063, United States
  • 972-865-2219